DI Mobile Menu


ECR 2009

Mergers and Acquisitions in Radiology

Everything radiologists need to know about the continuing trend of mergers and acquisitions.

©Biro Emoke/Shutterstock.com

ECR 2009

If radiologists could design the perfect modality for guiding interventional procedures, the resulting technology would undoubtedly produce high-quality images without exposing patients to any ionizing radiation. So given the widespread availability of MRI, why are so many interventions still performed in the angiography suite?

It wasn’t too long ago that ultrasound was a roiling sea of innovation and new product releases, spurred by a rivalry among Diasonics, ATL, Hewlett-Packard (Agilent Technologies), and Acuson. Since these companies’ acquisition by GE, Philips, and Siemens, the waters have calmed. Supersonic Imagine plans to begin making some waves -- and soon.

Rheumatoid arthritis, which affects approximately 2.9 million people in Europe, can be difficult to differentiate from other forms of arthritis. Without an early diagnosis, however, it is impossible to assess the true effect of promising early intervention strategies. Could an alternative diagnostic imaging strategy be the answer?

Crystal-ball gazing reached new levels at ECR on Saturday, when Prof. Dieter Enzmann took delegates on “a trip to radiology Tomorrowland,” as he referred to his W.C. Röntgen honorary lecture.

Radiologists should be clinically focused when handling HIV cases, according to a leading chest expert. They must know if patients are drug-naïve or whether they are already on antiretroviral therapy. It is also important to determine how they acquired their HIV, whether onset is acute or more gradual, and how profoundly unwell the patients feel.

The first ECR meeting that I attended was in 1999. I had started a CT practice in a hospital in Mumbai in 1995 with a conventional CT scanner and when it was time to upgrade to a spiral CT scanner, my wife and I thought it would be a good idea to attend an international conference. After our experience at the RSNA in Chicago in 1994, which had left us with severe sensory and physical overload from running from one place to another, trying to attend everything at once, a smaller meeting seemed more appealing.

Yes, size does matter, but it is certainly not the only way to monitor the efficacy of cancer treatment. The way in which lesions are measured is extremely important as well, ECR delegates were told at a special focus session on the assessment of tumor response.


Subscribe to ECR 2009 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.